Effect of high polyphenol extra virgin olive oil on markers of cardiovascular disease risk in healthy Australian adults (OLIVAUS): A protocol for a double-blind randomised, controlled, cross-over study by Marx, Wolfgang et al.
Bond University
Research Repository
Effect of high polyphenol extra virgin olive oil on markers of cardiovascular disease risk in
healthy Australian adults (OLIVAUS)
Marx, Wolfgang; George, Elena S.; Mayr, Hannah L.; Thomas, Colleen J.; Sarapis, Katerina;
Moschonis, George; Kennedy, Greg; Pipingas, Andrew; Willcox, Jane C.; Prendergast, Luke
A.; Itsiopoulos, Catherine
Published in:
Nutrition and Dietetics
DOI:
10.1111/1747-0080.12531
E-pub ahead of print: 17/04/2019
Document Version:
Peer reviewed version
Link to publication in Bond University research repository.
Recommended citation(APA):
Marx, W., George, E. S., Mayr, H. L., Thomas, C. J., Sarapis, K., Moschonis, G., ... Itsiopoulos, C. (2019). Effect
of high polyphenol extra virgin olive oil on markers of cardiovascular disease risk in healthy Australian adults
(OLIVAUS): A protocol for a double-blind randomised, controlled, cross-over study. Nutrition and Dietetics.
https://doi.org/10.1111/1747-0080.12531
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 27 May 2020
1 
Abstract 1 
Background: Previous clinical studies have suggested that high polyphenol extra virgin 2 
olive oil provides a superior cardioprotective effect compared to low polyphenol olive 3 
oil. However, further studies are required to replicate these results in non-Mediterranean 4 
populations. 5 
Aim: To investigate the effect of high polyphenol extra virgin olive oil vs low polyphenol 6 
olive oil with known polyphenol composition on markers of cardiovascular disease risk 7 
in a healthy non-Mediterranean cohort. 8 
Method: In a double-blind randomised cross-over trial, this study will examine the effect 9 
of high polyphenol extra virgin olive oil versus low-polyphenol olive oil in 50 healthy 10 
participants. Each intervention phase will be 3 weeks long with a 2-week washout period 11 
between each phase. Outcomes to be assessed include HDL cholesterol efflux, oxidized–12 
LDL, blood lipids, C-reactive protein, arterial stiffness, blood pressure, and cognitive 13 
function. Dietary intake, physical activity levels and anthropometry will also be collected. 14 
Discussion: Due to the rigorous trial design, novel and clinically relevant outcomes, the 15 
use of a well-characterised extra virgin olive oil, and, in contrast to the current literature, 16 
the non-Mediterranean study population, this study will provide a significant contribution 17 
to the understanding of the clinical importance of polyphenol intake in the Australian 18 
socio-cultural context. 19 
Keywords: olive oil, cognition, oxidative stress, polyphenol, biophenol, Mediterranean 20 
diet, 21 
22 
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1 Introduction 1 
The traditional Mediterranean diet, known for its cardioprotective effect, has been shown 2 
to improve cardiovascular disease risk factors including specific measures of blood lipids 3 
(HDL cholesterol, triglycerides), markers of inflammation, blood pressure, fasting blood 4 
glucose and risk of diabetes.1, 2 The traditional Mediterranean diet is characterised by an 5 
abundance of plant foods (e.g. leafy greens, tomatoes, onions, herbs, wholegrain cereals, 6 
legumes and nuts), moderate amounts of fermented dairy foods, seafood, red wine and 7 
small quantities of red meat and home-made sweets.3-5 Of particular relevance to the 8 
proposed study, is the large servings of extra virgin olive oil (EVOO; 60-80ml daily) as 9 
the primary source of culinary fat and a unique culinary component of the Mediterranean 10 
dietary pattern. Olive oil contains highly variable concentrations of polyphenols which 11 
can be affected by season, olive variety, region and soil, ripeness of the fruit and 12 
processing.6 EVOO is characterised by a low-temperature, mechanical processing 13 
technique which preserves the higher polyphenol content in comparison to the refining 14 
methods such as deodorization and chemical processing techniques used to produce 15 
refined olive oils, which subsequently have significantly lower polyphenol content.7, 8 16 
In healthy adults, EVOO has been shown to improve CVD risk factors including blood 17 
pressure, low grade inflammation, and lipid profile.9 The cardioprotective properties of 18 
EVOO have been primarily attributed to the high monounsaturated fat content; however, 19 
EVOO contains an array of unique polyphenols, also referred to as “biophenols”.10 These 20 
polyphenols have shown improvements in measures of glucose metabolism, lipid 21 
peroxidation, and cholesterol markers in clinical trials.11-14 Despite this evidence, the 22 
unique, cardioprotective polyphenols in EVOO are not currently recognised by 23 
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cardiovascular disease guidelines, possibly due to the need for additional high-level 1 
evidence.  2 
To further understand the mechanisms involved in the cardioprotective effect of EVOO-3 
derived polyphenols, further clinical research is needed to: (1) replicate previously 4 
reported improvements in routinely measured cardiovascular markers (e.g. HDL/LDL 5 
cholesterol, blood pressure) in the Australian population, (2) determine the feasibility of 6 
a provision of 60ml of EVOO per day in a non-Mediterranean population, and (3) 7 
investigate the effect of high-polyphenol EVOO on novel CVD risk markers. Increased 8 
CVD risk has, in part, been attributed to low plasma levels of HDL cholesterol (HDL-9 
C).15 However, emerging evidence suggests that impaired HDL function, rather than low 10 
HDL-C, may explain HDL-associated CVD risk.16 HDL-C efflux, as measure of HDL 11 
function, has been identified as a marker that may independently predict risk of CVD.17 12 
To improve the existing evidence-base in this area, the proposed trial aims to investigate 13 
the effect of a high-polyphenol EVOO compared to a low-polyphenol olive oil on both 14 
routinely measured (e.g. blood pressure and cholesterol) and novel markers (e.g. HDL-15 
cholesterol efflux) on CVD risk in a healthy Australian cohort.  16 
Furthermore, recently published clinical and animal studies have provided preliminary 17 
evidence to suggest that EVOO, as well as other polyphenol-rich interventions, may 18 
improve cognitive performance and prevent age- or experimentally-induced cognitive 19 
impairment.18, 19 Hence, as a secondary outcome, this study will also investigate the effect 20 
of high polyphenol EVOO and low polyphenol olive oil on measures of cognitive 21 
performance in this healthy cohort. 22 
2 Methods 23 
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The OLIVAUS study is a double-blind, randomised, controlled cross-over trial that aims 1 
to investigate the effect of a 3-week intervention of high polyphenol EVOO compared to 2 
a retail-purchased low polyphenol olive oil on CVD risk factors in 50 healthy participants 3 
(Fig. 1). Compared with a low polyphenol olive oil, we hypothesise that a high polyphenol 4 
EVOO intervention will result in improved measures of HDL cholesterol efflux, oxidised 5 
LDL and low-grade inflammation in a healthy adult population. The trial protocol 6 
(registered 30/04/2018, updated 13/02/2019) has been prospectively registered with the 7 
Australia New Zealand Clinical Trials Registry <removed> and was created in 8 
accordance with the SPIRIT Statement.20 9 
This trial will be conducted in accordance with the Guidelines for Good Clinical Practice 10 
and the Declaration of Helsinki and CONSORT reporting guidelines. The trial team has 11 
obtained written approval for the protocol and Patient Information and Consent Form 12 
from the <removed> University Human Research Ethics Committee (HEC17-067).   13 
Participants will be recruited in Melbourne, Australia using social media advertisements, 14 
and through <removed> University using email advertisements, mailing lists, word of 15 
mouth, and posters on campus and at local medical clinics. Table 1 provides the inclusion 16 
and exclusion criteria for this study. 17 
Figure 1 provides a visual representation of the study flow. The participant schedule 18 
throughout the trial is shown in Table 2, including data collection time-points. Once 19 
enrolled, participants will be asked to undergo an initial washout period where they will 20 
be instructed to abstain from consuming all olive oil, olive products, and antioxidant 21 
supplements for two weeks prior to the scheduled baseline meeting (T1). Participants will 22 
be requested to complete a 3-day diet diary including 2 week days and one weekend day 23 
where they are asked to include details on the foods and beverages consumed including 24 
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type, brand, quantity in household measures and cooking methods. Participants will be 1 
asked to complete this diet diary in the days preceding the initial appointment and at the 2 
conclusion of the intervention phases. Participants will be asked to come to the baseline 3 
meeting in a fasted state. At the end of each intervention phase, participants will receive 4 
a $25AUD gift voucher ($50AUD in total). 5 
The research staff will screen against the eligibility criteria during a face-to-face meeting. 6 
Following informed consent, participant numbers will be assigned sequentially and will 7 
be block randomised to receive either high polyphenol EVOO or low polyphenol olive 8 
oil. The block randomisation sequence will be developed using blocks of 6, by a senior 9 
researcher (<removed>), who will not have any direct involvement in the participant 10 
recruitment or data collection phase. After baseline measures are taken, a researcher who 11 
is not involved in any participant contact (<removed>) will email the allocation for each 12 
participant to the team. De-identified bottles of high and low polyphenol olive oil will be 13 
randomised and coded prior to the recruitment phase and all staff will be blinded to this 14 
randomisation.  15 
Participants will receive a 3-week supply of the either the low polyphenol olive oil or 16 
high-polyphenol EVOO (1.26 litres) at the commencement of the first intervention (T1) 17 
and the commencement of the second intervention (T4). Participants will be required to 18 
consume 60 ml per day for each of the 3-week intervention phases. Measuring cups will 19 
be provided for participant use, where appropriate, to demonstrate the required volume. 20 
Emphasis on strategies that incorporate olive oil into their habitual diet in a raw, uncooked 21 
form will be provided by researchers. This will include dressing salads or vegetables, 22 
drizzling the oil on prepared meals such as soups or casseroles, and ensuring leftover 23 
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amounts are also consumed. Participants will be supplied with the full amount of EVOO 1 
and olive oil required per 3-week intervention period. 2 
Total polyphenol and polyphenol subclasses for each olive oil intervention were analysed 3 
by Modern Olives Laboratory Services (Lara, VIC), a Commonwealth Government 4 
accredited testing agency, using high-performance liquid chromatography (HPLC). 5 
Samples were prepared and blinded for the researcher. Table 3 provides a comparison of 6 
the total polyphenol and polyphenol subclasses of each olive oil intervention. All high 7 
polyphenol EVOO was sourced from Cobram Estate Pty. Ltd. from the same harvest and 8 
lot and stored under the same conditions. An EVOO with a confirmed polyphenol count 9 
of approximately 320ppm will be provided to participants as the high polyphenol EVOO 10 
intervention. A low polyphenol olive oil was sourced from a local supermarket where a 11 
bulk purchase of the same brand from the same lot number was made. This oil was 12 
confirmed to have a polyphenol count of approximately 86 ppm. 13 
At the commencement of the first and second intervention phase meeting (T1 and T4), 14 
participants will attend a one-hour appointment in the morning with the research staff at 15 
the nutrition clinical rooms, <removed> campus, <removed> University. Data collection 16 
including three-day diet diaries, medical history and lifestyle (e.g. physical activity) 17 
questionnaires, anthropometry, fasting blood collection, blood pressure, arterial stiffness 18 
measures and cognitive performance will take place at each face to face appointment. 19 
Basic demographic data will also be collected at baseline including age, gender, and 20 
ethnicity. These are described in further detail below. 21 
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The research staff will contact participants by phone or email approximately 1.5 weeks 1 
into each intervention phase to discuss progress, adherence to the intervention and to ask 2 
participants if they have experienced any adverse events during the study period. 3 
At the end of each intervention phase (T3 and T6) participants will attend a face to face 4 
appointment where they will complete all the data collection indicated at the T1 and T3 5 
appointment. In addition, participants will be required to return their olive oil bottles so 6 
that research staff can record the weight of any remaining oil as an additional marker of 7 
adherence. 8 
For T3 only: Research staff will instruct the participants to undergo a 2-week washout 9 
period whereby they cease consumption of all olive oil and olive products during this 10 
period, until their next meeting (T4, start of second olive oil phase). 11 
For T6 only: Research staff will assess blinding by asking the participant about the order 12 
they think they received the two olive oil interventions and whether there were any 13 
differences in taste. 14 
All outcomes described below will be measured pre and post the olive oil intervention 15 
phases (T1, T3, T4, T6) as per Table 2. Blood collection will also take place at each pre 16 
and post time point. Research staff will confirm that participants have fasted for 8-12 17 
hours. If so, fasting venous blood samples will be obtained, by a researcher trained in 18 
venepuncture, from the antecubital vein using standard venous puncture techniques. If 19 
blood collection is unsuccessful research staff will arrange for blood collection at a local 20 
pathology centre within 48 hours of the scheduled appointment. 21 
HDL cholesterol efflux, the primary outcome, will be analysed using a Cholesterol Efflux 22 
Fluorometric Assay Kit (Biovision, USA). Participants will be invited to participate in an 23 
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optional cognitive performance assessment. If they have consented to this aspect of the 1 
trial, the participant will conduct the full cognitive assessment at each face to face 2 
appointment. The Swinburne University Computerised Cognitive Assessment Battery 3 
(SUCCAB) is a validated, computer based cognitive battery, administered using a 5-4 
button control box.21 Eight tests of cognitive function will be assessed by both accuracy 5 
and response time. These tests include Simple and Choice Reaction Times, Immediate 6 
and Delayed Recognition, Congruent and Incongruent Stroop colour-words, Spatial 7 
Working Memory and Contextual Memory. This battery has been used in numerous 8 
studies to assess the cognitive effects of dietary supplementation and other 9 
interventions.22-24 10 
Total, HDL, and LDL cholesterol, high sensitivity C-reactive protein and triglyceride 11 
levels will be measured using standard enzyme assays. Oxidized LDL will also be 12 
analysed using a solid phase two-site enzyme immunoassay (ELISA; Mercodia™, 13 
Sweden). 14 
Cardiovascular function will be assessed using the non-invasive SphygomoCor XCEL 15 
system (AtCor Medical, Australia) once the participant has rested for five minutes in the 16 
supine position. Assessments will include standard brachial blood pressures, aortic 17 
(central) blood pressures, pulse wave analysis of peripheral arterial stiffness, and carotid-18 
femoral pulse wave velocity analysis of central arterial stiffness.  19 
Three-day diet diaries will be collected at each face to face appointment. Research staff 20 
will conduct a baseline interview with all participants and will confirm that they 21 
underwent the required 2-week washout period. The research staff will also review the 3-22 
day dietary intake data to ensure sufficient detail has been recorded for nutrient analysis 23 
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and to clarify any missing data on responses that look inaccurate. Participants will self-1 
report details regarding their intake of food and liquids over a three-day period including 2 
the quantity (via household measures), type, and timing of items consumed. Furthermore, 3 
a specific section to capture timing and amount of olive oil will be incorporated. 4 
Participant weight, height and waist circumference will be measured using standard 5 
techniques, in duplicate by the research staff. If there is >10% variation between the two 6 
measures, a third measure will be obtained. The mean of the closest two measures will be 7 
used. Self-reported physical activity will be completed prior to the commencement of the 8 
trial (T1) and at the end of the trial (T6) via the Active Australia Survey,25 a validated 9 
tool within the Australian population and consists of 8 questions to assess the previous 7 10 
days. The questionnaire captures a range of activity types including walking, work in the 11 
yard, vigorous physical activity and moderate physical activity. Adverse events will be 12 
monitored at all time points. If a participant experiences significant adverse events, they 13 
will be withdrawn from the study. All adverse events will be reported to the trial steering 14 
committee, comprised of the Principal Investigator and trial staff. The Human Research 15 
Ethics Committee will also be notified, as appropriate. Emergency unblinding will occur 16 
for serious adverse events deemed related to the study product. All participant data will 17 
be securely stored either in onsite locked cabinets or password protected documents on 18 
secured university servers with restricted access to the study team only. 19 
All outcomes will be analysed by using linear mixed-effects (LME) models with random 20 
intercepts and slopes to account for within-participant correlation over time and varying 21 
treatment effect amongst participants. The effect of intervention order, due to potential 22 
carry-over effect, on all outcomes will be tested and adjusted for in the LME model if 23 
necessary by including and interaction term between the treatment and period effects. A 24 
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senior statistician (<removed>) will oversee the fitting of the LME models and be 1 
responsible for assessing model validity.  2 
Participant 3-day dietary records will be analysed and dietary changes will be used as a 3 
covariate. Adjusted results will be calculated using a multiple linear regression model 4 
including the stratification factors (e.g. gender, physical activity levels). A sensitivity 5 
analysis comparing the LME analyses and pooled estimates from the multiple imputation 6 
procedures will be conducted to prevent against bias. All reported P-values will be 2-7 
tailed. The levels of statistical significance will be set at P<0.05 and estimates will be 8 
accompanied with 95% confidence intervals. All statistical analyses will be conducted 9 
using the SPSS statistical software for Windows (version 25). Based on the results of 10 
previous research, a sample size of 40 was considered adequate to provide sufficient 11 
statistical power to detect a statistically significant 5% difference in HDL cholesterol 12 
efflux between the two intervention phases with 80% power and 5% level of 13 
significance.26 To account for a 20% level of potential attrition, this sample size was 14 
expanded to 50 participants.  15 
3 Results  16 
Recruitment commenced in July 2018 and is expected to be completed by late-2019. 17 
Currently, a total of n = 21 participants have been enrolled in this trial, leading to an 18 
average recruitment rate of 7 per month. Sixty five percent of participants are female with 19 
a mean age of 37 years. Five of the currently recruited cohort have completed the 20 
intervention with 100% of outcome data collected. Incomplete data have been collected 21 
on one participant due to withdrawal from the study due to inability to consume the 22 
required amount of olive oil. Ten percent of participants that have completed the 23 
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intervention consumed at least 80% of the provided oils. There have been no reported 1 
serious adverse events related to the study intervention. Reported adverse events include 2 
diarrhoea, bloating, reflux and heartburn. 3 
4 Discussion 4 
Previous clinical studies have reported that EVOO provides a cardioprotective effect 5 
through mediating improvements in cardiovascular risk factors;1, 9 however, few studies 6 
have investigated the contribution of the polyphenol component of olive oil to these 7 
improvements. This study will compare the effect of high-polyphenol EVOO to low-8 
polyphenol olive oil on markers of CVD risk that are related to cholesterol transport and 9 
metabolism, LDL oxidation, blood pressure (peripheral and central), arterial stiffness, and 10 
inflammation, as well as measures of cognitive function. By implementing a study design 11 
that will be able to differentiate between the effect of polyphenols from the other 12 
components of olive oil (e.g. monounsaturated fat will remain consistent between study 13 
arms), this trial will provide important information regarding the effect of EVOO 14 
polyphenols on a range of cardiovascular risk factors and cognition. In contrast to the 15 
current literature which has predominantly been conducted within Mediterranean 16 
populations, this will assess the use of high-polyphenol EVOO in the Australian western 17 
socio-cultural context. In addition, previous research has primarily assessed the effect of 18 
a Mediterranean diet and EVOO in populations with existing co-morbidities such as 19 
coronary heart disease, type 2 diabetes, cancer and cognitive decline while this study aims 20 
to recruit healthy participants.2, 27 This study is one of the first trials to comprehensively 21 
assess the polyphenol composition within each of the oils provided to participants. Other 22 
studies, even those which compare oils with varying polyphenol content, do not report 23 
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the composition of the polyphenols contained within.9 Finally, this study will report HDL 1 
efflux, oxidised LDL and other biomarkers of CVD that have not been extensively studied 2 
in previous dietary intervention studies. If shown to be beneficial, this study will provide 3 
evidence for a widely-accessible, low-cost dietary intervention to reduce cardiovascular 4 
disease risk and will significantly contribute to the existing literature on the clinical 5 
importance of polyphenol intake.  6 
 7 
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Figure 1. Study flow 
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Table 1. Study eligibility criteria 
Inclusion criteria 
• Aged 18-75 years  
• BMI between 18.5-40 kg/m2 
Exclusion criteria 
• Non-English-speaking persons 
• Pregnant or lactating women  
• History of adverse reactions to olive oil  
• A habitual diet with ≥1 tablespoons of olive oil per day 
• Individuals following special diets vegetarian, coeliac, weight loss programs etc. 
• Diagnosed with any of the following conditions: hyperlipidaemia; diabetes mellitus; 
hypertension; inflammatory conditions (e.g. rheumatoid arthritis), intestinal disease 
(e.g. inflammatory bowel disease; irritable bowel syndrome), food intolerances, blood 
coagulation disorders, any cognitive or mood disorder, any other physiological 
condition or disease that could impair adherence. 
• Currently prescribed warfarin, anti-coagulant therapy, statin medications, all oral 
hypoglycaemic agents, insulin, immunosuppressant agents, antihypertensive agents, 
and nonsteroidal anti-inflammatory drugs, hormone replacement therapy, antibiotics  
• Inability to cease nutrient supplement consumption, with the exception of iron, 
calcium and vitamin D, for the trial duration 
• Unstable body weight with > 5kg weight fluctuations in the prior 3 months.  
• Special diet for medical reasons (e.g. gluten free for coeliac disease) 
• Current smoker  
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Exclusion criteria for the cognition testing component only 
• Currently prescribed anti-depressant medication. 
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Table 2: Study procedure and time points in the OLIVAUS trial 
Study procedure T0 T1 T2 T3 T4 T5 T6 
Timepoint 
description 
2-weeks pre-
baseline 
Baseline, 
commencement of 
first intervention 
Mid-
intervention 
contact 
End of first 
intervention 
(3-weeks post 
T1 and start of 
washout 
period) 
Commencement of 
second intervention 
and end of washout 
period 
Mid-
intervention 
contact 
End of first 
intervention 
(3-weeks post 
T3) 
Total duration of 
study procedures 
30 minutes 1 hour 10 minutes 1 hour 1 hour 10 minutes 30 minutes 
Method of data 
collection 
Telephone 
OR Patient 
interview 
Patient interview  
 
Telephone 
interview 
Patient 
interview 
Patient interview Telephone 
interview 
Patient 
interview 
Screened & 
consented 
✓*       
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Participant 
characteristics 
 ✓      
Delivery of 3-week 
olive oil 
 ✓   ✓   
Delivery of 
Participant 
Booklet 
 ✓   ✓   
Intervention 
consumed 
 ✓ ✓ ✓ ✓ ✓ ✓ 
HDL-efflux  ✓  ✓ ✓  ✓ 
Total, HDL, LDL, 
triglyceride levels 
 ✓  ✓ ✓  ✓ 
Oxidized LDL  ✓  ✓ ✓  ✓ 
hsCRP  ✓  ✓ ✓  ✓ 
Blood pressure  ✓  ✓ ✓  ✓ 
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Arterial stiffness  ✓  ✓ ✓  ✓ 
Dietary intake  ✓  ✓ ✓  ✓ 
Cognitive 
performance 
 ✓  ✓ ✓  ✓ 
Physical activity  ✓     ✓ 
Anthropometry  ✓  ✓ ✓  ✓ 
Adverse events  ✓ ✓ ✓ ✓ ✓ ✓ 
Blinding 
assessment 
      ✓ 
HDL, High Density Lipoprotein; hsCRP, high sensitivity C-Reactive Protein; LDL, Low Density Lipoprotein;  
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Table 3. Polyphenol composition of the HPOO and LPOO provided in the OLIVAUS 
trial 
Biophenols Units HPOO LPOO 
Hydroxytyrosol mg/kg 3.3 5.3 
Tyrosol mg/kg 2.5 5.1 
Vanillic acid + 
Caffeic acid 
mg/kg 3.5 0.0 
Vanillin mg/kg 2.9 0.6 
p-Coumaric Acid mg/kg 13.0 1.0 
Hydroxytyrosol 
Acetate 
mg/kg 0.0 0.0 
Ferulic acid mg/kg 9.8 0.8 
o-Coumaric Acid mg/kg 0.0 0.0 
Decarb. 
oleuroaglycone, Ox Al 
mg/kg 6.5 2.7 
Oleacein mg/kg 71.7 6.3 
Oleuropein mg/kg 17.2 1.0 
Oleuro aglycone, Al mg/kg 11.0 0.8 
Tyrosol Acetate mg/kg 2.9 0.1 
Decarb. 
Ligstraglycone, Ox Al 
mg/kg 11.6 3.8 
Oleocanthal mg/kg 29.5 11.2 
Pinoresinol + 1 mg/kg 26.0 5.5 
This is a post-peer-review, pre-copyedit version of an article published in Nutrition and Dietetics.  
The final authenticated version is available online at: https://doi.org/10.1111/1747-0080.12531.  
This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions
22 
 
Acetoxy pinore 
Cinnamic Acid mg/kg 3.7 2.0 
Ligstroside 
aglycone, Al 
mg/kg 3.2 0.4 
Oleuro aglycone, 
Ox Al Hy 
mg/kg 13.8 3.0 
Luteolin mg/kg 13.9 1.8 
Oleuro aglycone, Al 
Hy 
mg/kg 44.6 3.0 
Ligstro aglycone, 
Ox Al Hy 
mg/kg 6.4 1.4 
Apigenin mg/kg 9.3 1.0 
Methyl-Luteolin mg/kg 5.0 3.0 
Ligstroside 
aglycone, Al Hy 
mg/kg 9.0 7.9 
Total Biophenols - 
HPLC 
mg/kg 320.3 86.4 
HPOO, High polyphenol olive oil; HPLC, High performance liquid chromatography; 
LPOO, low polyphenol olive oil 
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